No Data
MAIA Biotechnology Announces The Publication Of Preclinical Data For Its Lead Proprietary Telomere-Targeting THIO Dimer In The Peer-Reviewed Scientific Journal Naunyn-Schmiedeberg's Archives Of Pharmacology; Novel THIO Dimer Shows Promise As A New...
MAIA Biotechnology Announces USAN Approval Of Ateganosine As Generic Name For Lead Molecule THIO, A Telomere-Targeting Anticancer Agent For Advanced NSCLC Treatment In FDA Process
Express News | Maia Biotechnology Inc - to Retain Name Thio in Clinical Trial Designations
Express News | Maia Biotechnology Receives Usan Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent Thio
Express News | Maia Biotechnology Inc: Lans to Initiate a Phase 3 Pivotal Trial in 2025, Named Thio-104
MAIA Biotechnology Announces Design For Expansion Of THIO-101 Phase 2 Trial In Advanced Non-Small Cell Lung Cancer; To Enroll Patients In The U.S. And Select Countries In Europe And Asia
